ELK1 and cancer: The JNK interacting partner, Elk-1, is one of the critical downstream components of the Ras-MAPK pathway, but efforts to target this pathway using Ras or MEK inhibitors have failed to produce clinical benefits in CRCs and many other types of cancers[89].